Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: Preliminary findings

被引：46

作者：

Blier, P

Bergeron, R

机构：

[1] Neurobiological Psychiatry Unit, McGill University, Montréal, Que. H3A 1A1, 1033, Pine Avenue West

来源：

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY | 1996年 / 11卷 / 01期

关键词：

serotonin reuptake inhibitors; antidepressant drugs; serotonin receptors; tryptophan; pindolol;

D O I：

10.1097/00004850-199603000-00005

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Given that an important proportion of patients with obsessive-compulsive disorder (OCD) fail to respond adequately to serotonin (5-HT) reuptake inhibitors (SRI), augmentation strategies aimed at enhancing further 5-HT transmission by different mechanisms were attempted sequentially in 13 SRI-resistant patients. Addition of the 5-HT1A/beta-adrenergic antagonist pindolol did not alter OCD symptomatology but produced a rapid improvement of depressive symptoms. The 5-HT1A agonist buspirone as well as 5-hydroxytryptophan, the immediate precursor of 5-HT, added to the SRI-pindolol regimen, were not effective in attenuating the intensity of OCD. Tryptophan, added to the SRI-pindolol regimen, produced a significant improvement after 4 weeks, with further amelioration after 6 weeks (36% decrease of the Yale-Brown Obsessive Compulsive Score), which was maintained with treatment prolongation.

引用

页码：37 / 44

页数：8

共 43 条

[21]

JOFFE RT, 1993, ARCH GEN PSYCHIAT, V50, P387

[22] THE EPIDEMIOLOGY OF OBSESSIVE-COMPULSIVE DISORDER IN 5 UNITED-STATES COMMUNITIES [J].

KARNO, M ;

GOLDING, JM ;

SORENSON, SB ;

BURNAM, MA .

ARCHIVES OF GENERAL PSYCHIATRY, 1988, 45 (12) :1094-1099

[23] THE ANTIOBSESSIONAL EFFECTS OF CLOMIPRAMINE DO NOT REQUIRE CONCOMITANT AFFECTIVE-DISORDER [J].

KATZ, RJ ;

DEVEAUGHGEISS, J .

PSYCHIATRY RESEARCH, 1990, 31 (02) :121-129

[24]

LEONARD HL, 1991, ARCH GEN PSYCHIAT, V48, P922

[25]

MARKOVITZ PJ, 1990, AM J PSYCHIAT, V147, P798

[26]

MCDOUGLE CJ, 1993, AM J PSYCHIAT, V150, P647

[27]

MCDOUGLE CJ, 1991, J CLIN PSYCHOPHARM, V11, P175

[28]

MONTGOMERY SA, 1992, EUROPEAN NEUROPSY S2, V2, P384

[29]

MONTGOMERY SA, 1994, CURRENT INSIGHTS OBS, P215

[30]

Montgomery SA, 1980, PHARM MED, V1, P189

← 1 2 3 4 5 →